Results 281 to 290 of about 63,359 (335)
Mutational Hotspot of TET2, IDH1, IDH2, SRSF2, SF3B1, KRAS, and NRAS from Human Systemic Mastocytosis Are Not Conserved in Canine Mast Cell Tumors
, 2015 Eleonora Zorzan, Katia Hanssens, Mery Giantin, Mauro Dacasto, Patrice Dubreuil +4 moreopenalex +2 more sourcesPhase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma. [PDF]
Clin Cancer ResTap WD, Cote GM, Burris H, Gore L, Elias A, Beeram M, Conley AP, Gianolio DA, Qu Z, Pandya S, Trent JC. +10 moreeuropepmc +1 more sourceEx Vivo Experiments Show That IDH1/2-Mutant Inhibitors Can be Safely Used As Adjuvants to Regular Chemotherapy in IDH1/2-Mutated Acute Myeloid Leukemia
, 2015 Remco J. Molenaar, Bhumika J. Patel, Mohammed Khurshed, Bartlomiej Przychodzen, Srinivasa Reddy Sanikommu, Hetty E. Carraway, Tomas Radivoyevitch, Hideki Makishima, Cornelis J.F. Van Noorden, Jaroslaw P. Maciejewski +9 moreopenalex +1 more sourceHotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.
Cancer Cell, 2012 D. Sturm, H. Witt, H. Witt, V. Hovestadt, Dong-Anh Khuong-Quang, David T. W. Jones, Carolin Konermann, E. Pfaff, M. Tönjes, M. Sill, S. Bender, M. Kool, M. Zapatka, N. Becker, M. Zucknick, T. Hielscher, Xiao-yang Liu, A. Fontebasso, M. Ryzhova, S. Albrecht, K. Jacob, M. Wolter, M. Ebinger, M. Schuhmann, T. Meter, M. Frühwald, H. Hauch, A. Pekrun, B. Radlwimmer, T. Niehues, G. V. Komorowski, M. Dürken, A. Kulozik, J. Madden, A. Donson, N. Foreman, R. Drissi, M. Fouladi, W. Scheurlen, A. Deimling, A. Deimling, C. Monoranu, W. Roggendorf, C. Herold‐Mende, A. Unterberg, C. Kramm, J. Felsberg, C. Hartmann, B. Wiestler, W. Wick, T. Milde, T. Milde, O. Witt, O. Witt, Anders M. Lindroth, J. Schwartzentruber, D. Faury, A. Fleming, M. Zakrzewska, P. Liberski, K. Zakrzewski, P. Hauser, M. Garami, Á. Klekner, L. Bognár, Sorana A. Morrissy, F. Cavalli, Michael D. Taylor, P. Sluis, J. Koster, R. Versteeg, R. Volckmann, T. Mikkelsen, K. Aldape, G. Reifenberger, V. Collins, J. Majewski, A. Korshunov, P. Lichter, C. Plass, N. Jabado, S. Pfister, S. Pfister +82 moresemanticscholar +1 more sourceThe common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Cancer Cell, 2010 P. Ward, Jay L. Patel, David R. Wise, O. Abdel-Wahab, Bryson D. Bennett, H. Coller, J. Cross, V. Fantin, C. Hedvat, A. Perl, J. Rabinowitz, M. Carroll, Shinsan M. Su, K. Sharp, R. Levine, C. Thompson +15 moresemanticscholar +1 more source
